Cardiovascular risk established according to the recommendations of the European Society of Cardiology (ESC) 2021-2022.
Risk of drug–drug interactions determined based on pharmacological analyses conducted by the Institut de Cancérologie de l’Ouest (ICO), data from Drugs.com and the literature review published by the European Society for Medical Oncology (ESMO) (2024)
If the usual treatment is absent from the list: risk of interactions unknown at this time.
The results provided regarding the risk of drug interactions are for informational purposes only and are based on the literature available at the time of the last update of the PROTHEICA website.
Drug interactions are complex phenomena, involving various mechanisms, making it difficult to predict clinical outcomes accurately.
As a result, the interpretation and use of this information are the sole responsibility of the prescriber.
EN
